Departamento de Cirurgia Neurológica, Hospital das Clínicas, Faculdade de Medicina, Universidade Federal de Goiás, Goiânia, GO, Brasil.
Serviço de Cirurgia Neurológica, Hospital do Câncer Araújo Jorge, Goiânia, GO, Brasil.
Arch Endocrinol Metab. 2023 Jun 19;67(6):e000650. doi: 10.20945/2359-3997000000650.
The primary aim is to analyze the endoscopic endonasal surgical results in short-term and two-year follow-ups according to the 11th Acromegaly Consensus statement (2018). Indeed, prognostic factors and complications were analyzed.
40 patients who underwent endoscopic endonasal surgery by acromegaly between 2013 to 2020 was analyzed. Patients were considered in remission if an upper limit of normal (ULN) IGF-1 was less than 1.0 at the six-month and two-year follow-ups. Moreover, we assessed the Knosp grade, tumor volumetry, ULN, T2 signal in MRI, reoperation, and complications.
The mean age of admission was 46.7 years. Thirty-two patients were in remission after six months of surgery (80%), decreasing to 76.32% at the two-year follow-up. All microadenomas presented remission (n = 6). Regarding the complications, three patients had permanent panhypopituitarism (7.5%); postoperative cerebrospinal fluid (CSF) leaks did not occur in this series. The hyperintense signal on the T2 MRI and a higher tumor volumetry were the single predictor's factors of non-emission in a multivariate regression logistic analysis (p < 0.05). Preoperative hormone levels (GH and IGF-1) were not a prognostic factor for remission. The re-operated patients who presented hypersignal already had a high predictor of clinical-operative failure.
The endoscopic endonasal surgery promotes high short-term and two-year remission rates in acromegaly; the tumor's volumetry and the T2 hypersignal were statistically significant prognostic factors in non-remission - the complications presented at similar rates in comparison to the literature. In invasive GH-secreting tumors, we should offer these patients a multi-disciplinary approach to improve acromegalic patients' remission rates.
根据第 11 届肢端肥大症共识声明(2018 年),分析内镜经鼻手术的短期和两年随访的结果。事实上,分析了预后因素和并发症。
分析了 2013 年至 2020 年间接受内镜经鼻手术的 40 例肢端肥大症患者。如果患者在六个月和两年随访时 IGF-1 的上限低于正常上限(ULN),则认为其处于缓解状态。此外,我们评估了 Knosp 分级、肿瘤体积、ULN、MRI 的 T2 信号、再次手术和并发症。
入院时的平均年龄为 46.7 岁。32 例患者在手术后六个月(80%)缓解,两年随访时降至 76.32%。所有微腺瘤均缓解(n = 6)。关于并发症,有 3 例患者出现永久性垂体功能减退症(7.5%);本系列无术后脑脊液(CSF)漏。在多变量回归逻辑分析中,T2 MRI 上的高信号和更高的肿瘤体积是未缓解的单一预测因素(p < 0.05)。术前激素水平(GH 和 IGF-1)不是缓解的预后因素。已经出现高信号的再次手术患者已经具有临床手术失败的高预测性。
内镜经鼻手术可促进肢端肥大症的短期和两年高缓解率;肿瘤体积和 T2 高信号是未缓解的统计学显著预后因素——与文献相比,并发症发生率相似。在侵袭性 GH 分泌性肿瘤中,我们应该为这些患者提供多学科方法,以提高肢端肥大症患者的缓解率。